Bavarian Biotech GmbH

Bavarian Biotech is a spin-off from the Ludwig-Maximilians-University Munich. Our mission is to transform patient stratification in targeted cancer therapy with a focus on antibody-drug conjugate (ADC) therapies by providing innovative, functional biomarker solutions. Through our proprietary High-Affinity Probe Technology, we enable more precise patient selection, helping to optimize patient stratification, clinical trial designs and accelerate the development of targeted cancer therapies. Our goal is to improve the outcomes and quality of life for cancer patients of all ages and cancer types by delivering more accurate and actionable diagnostic insights.